REGENXBIO Inc.
RGNX · NASDAQ
Company research
REGENXBIO Inc. (NASDAQ: RGNX) is a clinical-stage biotechnology company headquartered in Rockville, Maryland, dedicated to improving lives through the curative potential of adeno-associated virus (AAV) gene therapy. The company's proprietary NAV Technology Platform encompasses exclusive rights to more than 100 novel AAV vectors, forming the foundation of its internal pipeline as well as its licensing business model, which includes partnerships with major pharmaceutical companies such as AbbVie and Nippon Shinyaku. Its late-stage pipeline targets rare and retinal diseases, with lead programs including ABBV-RGX-314 (in collaboration with AbbVie) for wet age-related macular degeneration and diabetic retinopathy, RGX-202 for Duchenne muscular dystrophy, and RGX-121 for mucopolysaccharidosis type II, among others. Founded in 2008 and led by CEO Curran Simpson, REGENXBIO operates a hybrid business model generating revenue through internal drug development, licensing royalties, and milestone payments, and boasts fully in-house capabilities spanning capsid discovery and engineering through commercial-scale manufacturing.
Research reports
Summarizes H.C. Wainwright’s reiterated Buy rating with a $26 price target on RGNX following positive RGX‑202 Duchenne microdystrophin and functional data, highlighting a favorable safety profile, correlation of biomarker and clinical outcomes, and supporting price targets from Leerink and Baird that collectively frame the stock as undervalued at current levels.
SahmCapital · May 14, 2026Cash Runway Risk Beside...Analyzes Q1 2026 results showing revenue of about $6.4 million, deepening losses, a trailing twelve‑month revenue decline versus prior quarters, and an implied cash runway of less than one year, arguing that while the P/S multiple is below peers, financing risk and volatile revenues create a bearish backdrop that can outweigh the late‑stage gene‑therapy pipeline for cautious investors.
Merlintrader Trading Pub · January 24, 2026RGNX RegenxbioFrames RGX‑121’s February 2026 PDUFA, AbbVie‑backed retina programs, and Duchenne RGX‑202 as three pillars of an equity story combining platform royalties and binary FDA events, emphasizing a balance sheet extended into early 2027 via upfront payments and royalty monetization and presenting RGNX as an attractive long‑term opportunity despite concentrated regulatory and execution risk.
BioEquity Watch (Substack) · January 8, 2026DD: REGENXBIO ($RGNX)Provides a full due‑diligence report on RGNX’s NAV AAV8/AAV9 gene‑therapy platform, detailing late‑stage assets sura‑vec, RGX‑202, and RGX‑121, partnerships with AbbVie, Nippon Shinyaku, and royalty monetization, a cash and securities balance around $302 million with runway into early 2027, and multiple near‑term catalysts (PDUFA, pivotal readouts), concluding with an explicitly bullish stance that current valuation underprices de‑risked assets and upcoming events.
Merlintrader Trading Pub · December 22, 2025RGNX REGENXBIOCombines technical chart analysis placing RGNX at channel support with a fundamental preview of the February 8, 2026 RGX‑121 FDA decision for MPS II, arguing that the setup represents a favorable long entry ahead of a potentially landmark one‑time gene therapy approval that could materially re‑rate the equity if successful.
KoalaGains · November 3, 2025Regenxbio Inc. (RGNX) Future Performance AnalysisModels RGNX’s growth through 2035 across bull, base, and bear scenarios, stressing that future performance hinges almost entirely on ABBV‑RGX‑314 in wet AMD and diabetic retinopathy, and characterizing the stock as a speculative, binary outcome play where consensus revenue CAGRs above 100% contrast with expected negative EPS into at least 2027 and a narrow, high‑stakes clinical path.